HEMO Hemogenyx Pharmaceuticals Plc

TIDMHEMO

Hemogenyx Pharmaceuticals PLC

16 February 2022

16 February 2022

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

HEMO-CAR-T pre-IND Meeting Request

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") is to be deferred until May 2022 as a result of a general FDA policy prioritizing work on COVID-19. The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined. A pre-IND meeting will then be necessary only if the written responses leave any matters unresolved. In light of this written process now implemented by FDA, there is no anticipated impact from the deferment on the IND filing for HEMO-CAR-T.

As noted above, the process for pre-IND meetings has been amended by the FDA on a general basis, with the Agency stating as follows: "In response to the Coronavirus Disease 2019 (COVID-19) public health emergency, FDA's Center for Biologics Evaluation and Research (CBER) has taken steps to prioritize work that advances the nation's response during this national emergency."

In the meantime, work on manufacturability, quality, safety and other key parts of the development HEMO-CAR-T continue in an encouraging manner.

In addition, positive progress continues in relation to the Company's CDX bispecific antibody product candidate for the treatment of acute myeloid leukaemia, as well as its CBR platform product candidate, a novel cell-based platform technology for the treatment of emerging viral diseases and certain types of cancer. The Company will continue to notify shareholders as key stages with respect to all of its product candidates are reached.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "The process toward our IND application remains on track and the change in the FDA's process is not expected to affect the outcome of the IND application or timetable for clinical trials."

About AML and CAR-T Therapy

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective form of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of the new therapy for AML would have a major impact on treatment and survival rates for the disease.

CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   headquarters@hemogenyx.com 
 Peter Redmond, Director                 peter.redmond@hemogenyx.com 
 
                                         Tel: +44 (0)20 3470 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Adam Cowl 
 
                                         Tel: +44 (0)20 7469 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 
 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFSAFIIELIF

(END) Dow Jones Newswires

February 16, 2022 02:00 ET (07:00 GMT)

Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Hemogenyx Pharmaceuticals (LSE:HEMO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024